This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gregory A. Poland, MD; Robert M. Jacobson, MD; Aruna M. Thampy, RN; S. Ann Colbourne, MD; Peter C. Wollan, PhD; James J. Lipsky, MD; Steven J. Jacobsen, MD, PhD

JAMA. 1997;277(14):1156-1158.

Abstract
Objective.
—To evaluate the success of measles reimmunization in children without measles antibody after the initial dose of measles vaccine.

Design and Setting.
—A prospective clinical trial in Olmsted County, Minnesota, and Northern Newfoundland and Labrador in Canada.

Subjects.
—A total of 130 healthy white, Innu, and Inuit schoolchildren. All subjects had received the post-1980 Moraten measles vaccine 4 to 11 years earlier.

Methods.
—Children previously identified as measles antibody seronegative or equivocal after 1 dose of measles vaccine were entered into the trial and reimmunized. Measles antibody was measured a minimum of 6 weeks later using a whole-virus IgG measles-specific enzyme-linked immunoassay (EIA).

Results.
—Of the 130 children reimmunized, 106 (81.5%) became measles antibody seropositive, but 24 children (18.5%) remained seronegative. Younger age at initial immunization (<13 months vs 13 months) was significantly associated with lack of seropositive antibody levels following reimmunization (odds ratio, 3.9; 95% confidence interval, 1.5-9.7). In addition, antibody levels after reimmunization were significantly reduced with increasing time since initial immunization (P=.001).

Conclusions.
—After 2 doses of measles vaccine, 98.2% of all subjects in this study were seropositive for measles antibody, despite the fact that almost 20% of children did not have measurable antibodies 4 to 11 years following a first dose. These findings suggest that the current public health policy recommending a 2-dose measles immunization strategy, with the second dose given at school entry, will provide high levels of immunity in the community.

Author Affiliations
From the Mayo Vaccine Research Group (Drs Poland, Jacobson, and Lipsky), Department of Health Sciences Research (Drs Wollan and Jacobsen), Clinical Pharmacology Unit (Drs Poland and Lipsky), Department of Pediatric and Adolescent Medicine (Dr Jacobson), Mayo Clinic and Foundation, Rochester, Minn; Grenfell Regional Health Services (Ms Thampy), Department of Internal Medicine (Dr Colbourne), St Anthony, Newfoundland.

Footnotes
Dr Poland is a Mayo Rappaport Scholar awardee.

Presented in part at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla, October 4, 1994.

Reprints: Gregory A. Poland, MD, Mayo Clinic, 601B Guggenheim Bldg, 200 First St SW, Rochester, MN 55905.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Differing Immunization Policies on Circulating Measles Antibody Levels in US and Canadian Children
Poland et al.
Mayo Clin Proc. 2002;77:446-452.
ABSTRACT  

Immunology Series: Vaccines
Barton and Ada
NEJM 2002;346:864-866.
FULL TEXT  

Association of Parental Vaccination Reports With Measles, Mumps, and Rubella Protective Antibody Levels: Comparison of Somali Immigrant, Hispanic Migrant, and US Children in Rochester, Minn
Sauver et al.
Mayo Clin Proc. 2002;77:241-245.
ABSTRACT